AOD-9604Also known as: HGH Fragment 176-191

What Is AOD-9604?

AOD-9604 is a synthetic peptide consisting of the C-terminal fragment of human growth hormone (amino acids 176–191) with a tyrosine residue added to the N-terminus. It was originally developed by Metabolic Pharmaceuticals in Australia as a potential treatment for obesity.

The peptide was designed based on research showing that the 176–191 region of the HGH molecule is responsible for its lipolytic (fat-burning) activity, while the full HGH molecule's growth and metabolic effects are mediated by other regions that bind to the GH receptor. By isolating and modifying this fragment, researchers aimed to create a compound with HGH's fat-loss properties but without the insulin resistance, tissue growth, or IGF-1 elevation associated with full HGH use.

Mechanism of Action

AOD-9604 works through several complementary pathways that converge on adipocyte metabolism:

• Beta-3 adrenergic receptor activation: AOD-9604 stimulates beta-3 adrenergic receptors on adipocytes (fat cells), which triggers cyclic AMP (cAMP) production and activates hormone-sensitive lipase (HSL) — the enzyme that breaks down triglycerides into free fatty acids and glycerol for oxidation
• Inhibition of lipogenesis: AOD reduces the activity of enzymes involved in de novo lipogenesis (new fat synthesis), particularly acetyl-CoA carboxylase. This means less dietary energy is converted into stored fat
• No GH receptor binding: Unlike full HGH, AOD-9604 does not bind to GH receptors and therefore does not stimulate IGF-1 production, does not affect glucose metabolism or insulin sensitivity, and does not cause tissue growth or proliferation

The net effect is mobilization of stored fat for oxidation without the broader metabolic disruption of full growth hormone therapy.

Clinical Evidence

The clinical trial data on AOD-9604 is limited but generally supportive of lipolytic effects:

• Phase 2 trials (2004–2007): Multiple trials in overweight and obese adults showed modest weight loss with subcutaneous AOD administration (1mg daily) over 12 weeks. Weight loss averaged 2–3kg compared to placebo, with preferential fat loss (rather than lean mass). Importantly, no significant changes in blood glucose, insulin, or IGF-1 were observed, confirming the lack of GH receptor activity
• Phase 3 failure: A large Phase 3 trial was terminated early in 2007 due to failure to meet primary efficacy endpoints. The compound showed fat loss but not to the magnitude required for FDA approval as an obesity drug. This does not mean AOD is ineffective — it means it is not effective enough to replace diet and exercise as a standalone obesity treatment, which was the regulatory bar it needed to clear
• Animal studies: Extensive pre-clinical work in rodents and primates demonstrated significant fat reduction, particularly in visceral adipose tissue, without adverse effects on glucose homeostasis or growth

The practical takeaway: AOD-9604 has legitimate lipolytic activity, but the magnitude is modest. It is not a substitute for a caloric deficit and training — it is an adjunctive tool to optimize fat loss within an already-dialed protocol.

Dosing Protocol

The clinical trial dose was 1mg subcutaneous injection daily. In practice, most men use 250–500mcg per day, injected subcutaneously in the morning on an empty stomach. The fasted state is important because insulin inhibits lipolysis — taking AOD in a fed state negates much of its mechanism.

Timing: Administer 30–45 minutes before morning fasted cardio if possible. This maximizes fat oxidation by mobilizing fatty acids just before a caloric expenditure window. If fasted cardio is not part of your protocol, simply take it first thing in the morning before breakfast.

Duration: 8–12 week cycles are typical. There is no strong evidence for receptor desensitization at this duration, but cycling off for 4 weeks between cycles is a common precautionary practice.

Integration with Other Compounds

AOD-9604 is frequently stacked with:

• GLP-1 agonists (Semaglutide, Tirzepatide): GLP-1 agonists suppress appetite and slow gastric emptying, creating the caloric deficit. AOD enhances lipolysis during that deficit. This is a popular combination in aggressive fat-loss protocols
• CJC-1295 + Ipamorelin: GH secretagogues raise endogenous GH and IGF-1, which have anabolic and metabolic effects. AOD adds selective lipolysis. This stack is common in body recomposition where the goal is simultaneous fat loss and lean mass gain
• TRT: Testosterone supports lean mass preservation and training intensity during a cut. AOD + TRT is a straightforward fat-loss stack

Sourcing and Quality Control

AOD-9604 is not FDA-approved and is sold as a research peptide. Quality control is variable. Best practices when sourcing:

• Request a Certificate of Analysis (COA) showing HPLC purity testing — minimum 98% purity
• Verify peptide identity with mass spectrometry data if available
• Store lyophilized powder at -20°C (freezer) until reconstitution
• Once reconstituted with bacteriostatic water, store in refrigerator and use within 30 days

Many compounding pharmacies that specialize in peptide therapy now offer AOD-9604 alongside BPC-157, TB-500, and GH secretagogues. This is generally a more reliable source than gray-market research peptide vendors.